BGB-16673 is an investigational chimeric degradation activating compound (CDAC) targeting BTK. Watch the mechanism of action video (MoA) to learn more.

Watch this video to understand the mode of action of Chimeric Degradation Activating Compounds (CDAC), a new investigational targeted approach for hematologic malignancies.

Network Meta-Analysis (NMA) methodology is explained in this video hosted by Dr Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine. This video covers how to connect three or more trials using common comparators to estimate relative efficacy outcomes. Highlights include the practical use of NMA, differences between MAIC and NMA, and a worked through example using the ASCEND, ALPINE, and ELEVATE-RR trials in relapsed/refractory CLL (R/R CLL). This video is aimed at those interested in advanced health research methods.

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Matching Adjusted Indirect Comparison (MAIC) methodology. In this video, we explore the use of MAIC for comparing the efficacy of zanubrutinib vs. acalabrutinib, using patient level data from the ALPINE trial and published data from the ASCEND trial, respectively. Our results emphasize a few methodological aspects of MAICs, such as the parameters matched in the analysis, the effective sample size, importance of sensitivity analysis, data cut-offs used and the impact of COVID-19 where relevant. Perfect for those keen on advanced healthcare research.

Zanubrutinib is a next-generation Bruton’s tyrosine kinase inhibitor (BTKi) designed for selectivity, potency, and bioavailability. Watch the mode of action (MoA) video to learn more.